BMRA

Biomerica, Inc. (BMRA) 10-K Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended May 31, 2010. Biomerica, Inc. is a smaller reporting company incorporated in Delaware that develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care settings (physicians' offices and over-the-counter). The company operates manufacturing facilities in Irvine, California, and Mexicali, Mexico. During the fiscal year, the company eliminated its internal research department to focus on licensing technology from external institutions.

Key Financial Metrics

Note: Specific net income/loss figures were not explicitly stated in the provided text, though the company reported net income over the previous four fiscal years. The text indicates cash used in operations was $236,980 for 2010.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by 2.8% ($140,451) driven primarily by a $411,000 increase in Asian sales, which offset declines in other regions.
• Margin Compression: Gross margin decreased from 39.9% to 30.8%. Cost of sales as a percentage of revenue increased by 9.2% due to higher scrap rates from facility relocation, a $50,000 inventory write-down, increased rent, and costs associated with new product registration in China.
• Operational Shifts: The company moved its headquarters from Newport Beach to Irvine, incurring approximately $225,000 in direct moving costs and overlapping rent expenses. This move temporarily impacted production output.
• R&D Strategy: R&D expenses increased 63.5% to $455,171. The company eliminated its internal research group (two scientists) to accelerate product development through external technology licensing.
• Liquidity: Cash and cash equivalents decreased by approximately $540,000. Working capital declined by approximately $655,000.

Guidance, Outlook, and Risks

Outlook and Strategy: Management plans to continue expanding its product line through technology licensing rather than internal R&D. The company recently acquired exclusive licenses for new diagnostic technologies (e.g., thiopurine methyltransferase measurement) and entered into cross-license agreements. The company intends to retain earnings to finance operations and does not plan to pay cash dividends.

Risks and Contingencies:

• Customer Concentration: One customer accounted for 23.5% of consolidated sales in 2010. The loss of a major distributor could adversely affect results.
• Regulatory Compliance: Products are subject to FDA and international regulations. Failure to maintain compliance could result in fines, recalls, or suspension of production. Some products are sold internationally or "for research only" in the U.S. pending FDA clearance.
• Product Liability: The company faces risks associated with product liability claims, though it maintains insurance coverage.
• Intellectual Property: The company relies on licensing agreements and patents; there is a risk of third-party patent infringement claims or inability to protect proprietary rights in foreign jurisdictions.

Investor Verification Checklist

• Verify the specific net income or loss for the fiscal year ended May 31, 2010, as the text mentions profitability trends but does not explicitly state the final net income figure in the MD&A section provided.
• Confirm the status of FDA clearance for products currently sold "for research only" in the U.S., as this impacts future revenue potential.
• Review the details of the new technology licensing agreements (royalty rates of 4-8% and minimum escalating payments) to assess future cash flow obligations.
• Monitor the backlog, which dropped significantly from $97,000 to $8,000, indicating potential near-term revenue visibility issues.
• Assess the impact of the facility move on ongoing production efficiency and scrap rates, as these were cited as major drivers of margin compression.